Brief: Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study Of Lead Asset Ctx-1301 For Adhd
29/04/2025 14:22
April 29 (Reuters) - Cingulate Inc CING.O: CINGULATE ANNOUNCES POSITIVE TOP-LINE RESULTS FROM HIGH-DOSE (50MG) FED/FAST STUDY OF LEAD ASSET CTX-1301 FOR ADHD Source text: ID:nGNX2rWqz4 Further company coverage: CING.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cingulate
See all newsBrief: Cingulate Announces Publication Of Phase 3 Adhd Trial Results In Journal Of Child And Adolescent Psychopharmacology
NASDAQ RESUMED AT 09:39 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:34 AM
NASDAQ RESUMED AT 08:30 AM
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues (updated)